Eli Lilly CFO Anat Ashkenazi on managing soaring demand for GLP-1s

Eli Lilly CFO Anat Ashkenazi on managing soaring demand for GLP-1s

A pharmacist holds boxs of Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023.  George Frey | Bloomberg | Getty Images Skyrocketing demand for a class of weight loss and diabetes treatments has lifted Eli Lilly to new heights over the last year. … Read more

U.S. jobs report, ECB commentary

U.S. jobs report, ECB commentary

Stock price information reflected on a window at the Euronext NV stock exchange in Paris, France, on Monday, March 13, 2023.  Nathan Laine | Bloomberg | Getty Images LONDON — European stocks closed lower on Friday, as investors digested fresh U.S. jobs data and the European Central Bank’s latest interest rate commentary. The Stoxx 600 provisionally … Read more

ECB interest rate decision watched closely

ECB interest rate decision watched closely

A sculpture of the Euro currency stands in the city centre of Frankfurt am Main, western Germany, on January 25, 2024. Kirill Kudryavtsev | Afp | Getty Images European stocks were higher Thursday, with traders anticipating that the European Central Bank will cut borrowing costs for the euro area for the first time since September … Read more

Half of workers may struggle to get obesity drug insurance coverage

Half of workers may struggle to get obesity drug insurance coverage

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023. Brendan McDermid | Reuters Companies are increasing access to new blockbuster weight-loss drugs for employees, but size of employer may make a big difference in early access. Small businesses and their workers are often stuck … Read more

Ro launches GLP-1 supply tracker to help patients navigate shortages

Ro launches GLP-1 supply tracker to help patients navigate shortages

GLP-1 Supply Tracker from Ro.  Courtesy: Ro Telehealth company Ro on Wednesday launched a new tracker to help patients find a popular class of weight loss and diabetes drugs called GLP-1s amid shortages of those treatments in the U.S. The supply tracker could be a valuable tool for many Americans scrambling to get their hands … Read more

Weight loss drug ETF bets big on Eli Lilly, Novo Nordisk

Weight loss drug ETF bets big on Eli Lilly, Novo Nordisk

A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs. Roundhill Investments’ GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on … Read more

Digital health companies are launching programs around GLP-1s

Digital health companies are launching programs around GLP-1s

Patent protection for Wegovy — Novo Nordisk’s blockbuster weight loss drug, which contains the second generation GLP-1 active ingredient and is at least twice as effective — is expected to expire by the decade’s end. Michael Siluk | UCG | Getty Images For Gray Beard, a kindergarten teacher in Charlotte, North Carolina, losing weight had … Read more

Eli Lilly big GLP-1 investment — plus, CRM, BBY, FL, COST earnings next week

Eli Lilly big GLP-1 investment — plus, CRM, BBY, FL, COST earnings next week

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Wall Street was bouncing higher Friday after, as Jim Cramer put it, a “really bad day” in the prior session. Thursday’s late-day decline happened as bond yields rose on … Read more

Eli Lilly, Novo Nordisk develop weekly insulin

Eli Lilly, Novo Nordisk develop weekly insulin

A patient injects herself with an insulin pen. Guido Krzikowski | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! The rivalry between Eli Lilly and Novo Nordisk extends beyond a buzzy class of weight loss and diabetes drugs called GLP-1s.  … Read more

AstraZeneca to boost revenue, release new medicines by 2030

AstraZeneca to boost revenue, release new medicines by 2030

The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. Costfoto | Future Publishing | Getty Images LONDON — Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023. “We have … Read more